GlassScriptPhysician profile
Chady B Sarraf
NPI 1568600666
$533.22
in general payments reported to CMS, 2019-2025
12 companies · $89.13 in 2025
The $89.13 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2023: $147 · 2024: $122 · 2025: $89.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $147.69 | 2023-2025 | Teflaro |
| E.R. Squibb & Sons, L.L.C. | $79.04 | 2023-2024 | Eliquis, Camzyos |
| Recor Medical INC | $50.65 | 2024 | Paradise Renal Denervation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.18 | 2019 | |
| Abiomed | $39.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.87 | 2019 | |
| Merck Sharp & Dohme LLC | $28.16 | 2019 | |
| Allergan, INC. | $26.01 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.25 | 2024 | Jardiance |
| Pfizer INC. | $22.73 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.15 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chady Sarraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.